UNSPSC 51172413: Aluminum hydroxide/magnesium trisilicate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA103. This VA Drug Class (GA103) classifies this compound as belonging to the group ALUMINUM/MAGNESIUM CONTAINING ANTACIDS.

UNSPSC 51172413 Aluminum hydroxide/magnesium trisilicate is a Commodity code that in recent state and local procurement appears to support pharmaceutical and over-the-counter product sourcing rather than antacid ingredients specifically. The recent opportunities posted under this code reflect state and local demand for generic pharmaceuticals, OTC products, and pharmacy benefit program services, suggesting the code may be used broadly as a catch-all for pharmaceutical commodity acquisitions. State and local issuing bodies soliciting under the code include cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance), state health and human services commissions (Texas HHS Commission), and county corrections departments (Collin County Community Supervision and Corrections Department). The scope encompasses generic multi-source pharmaceuticals with specific National Drug Codes, OTC products distributed through authorized wholesalers, offender drug testing and specimen collection services with laboratory certification requirements, and exploratory capability-gathering for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels.

Recent activity clusters in Texas and Minnesota. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, and administrative fee adherence. The Texas Health and Human Services Commission posted an RFI on March 27, 2026 (due April 3, 2026) to gather vendor capability information for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional PBM and GPO relationships. Collin County Community Supervision and Corrections Department issued RFP 2026-327, due July 23, 2026, for offender specimen collection and drug testing services with an estimated contract value of $600,000, requiring SAMHSA, Texas DPS, or CAP lab certification and annual testing volume of approximately 25,031 tests across five-panel and six-panel screens with immunoassay and confirmatory testing methodologies.